FLYER Randomised study comparing 4 and 6 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day intervals (CHOP-21), both with 6 cycles of the monoclonal anti-CD20 antibody Rituximab in patients aged 18 to 60 years with aggressive Non-Hodgkin’s Lymphoma with no risk factor (aaIPI=0) and no bulky disease (<7.5 cm) DSHNHL 2004-2 (FLYER) years months Therapy arm Gender Age (years) IPI factor age>60 years IPI factor LDH>N IPI factor ECOG>1 IPI factor stage III/IV IPI factor extralymphatic involvement > 1 age-adjusted IPI score Extralymphatic involvement Bulky disease B-symptoms Bone marrow involvement Reference pathology diagnosis Event-free survival (months) Event-free survival status Progression-free survival (months) Progression-free survival status Overall survival (months) Overall survival status 6 x CHOP-21 + 6xR 4 x CHOP-21 + 6xR male female age <= 60 years age > 60 years LDH <= N LDH > N ECOG <= 1 ECOG > 1 stage I/ II stage III/ IV E <= 1 E > 1 no yes no yes no yes no yes centroblastic immunoblastic plasmoblastic anaplastic large cell (ALC) T-cell-rich B-cell lymphoma DLBCL NOS prim. mediast. B-cell lymphoma follicular lymphoma III° follicular lymphoma III° + DLBL Burkitt‘s lymphoma Mantle cell lymphoma (blastic) aggressive marginal zone lymphoma B-cell NOS B-cell, Unclassified (techn. insufficient mat.) low grade NHL no lymphoma Hodgkin‘s disease Composite lymphoma Lymphomatoid granulomatosis censored event censored event censored event